OMBITASVIR/PARITAPREVIR/RITONAVIR PLUS DASABUVIR TREATMENT EXPERIENCE IN HCV PATIENTS


Bayan K., ÇELEN M. K. , Dal T., AYAZ C., TEKİN R., Akdemir I., ...More

ACTA MEDICA MEDITERRANEA, vol.34, no.1, pp.71-75, 2018 (Journal Indexed in SCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 34 Issue: 1
  • Publication Date: 2018
  • Doi Number: 10.19193/0393-6384_2018_1_12
  • Title of Journal : ACTA MEDICA MEDITERRANEA
  • Page Numbers: pp.71-75

Abstract

Introduction: Achieving sustained virologic response (SVR) is critical in HCV patients. In current study, we aimed to investigate the efficacy and safety of DAA (OBV/PTV/r + DSV +/- RBV) treatment regimen in patients with HCV.